Backs FY24 revenue view $1.99B, consensus $1.98B. “Our 2024 results to date reflect a positive quarterly trend in sales and adjusted earnings, along with a 73% increase in free cash flow. We are well-positioned to achieve the updated outlook for 2024 as we once again increase our adjusted EPS target,” said Roland Sackers, CFO of Qiahen. “We are implementing initiatives to simplify QIAGEN (QGEN) and increase efficiency, and these initiatives are putting us on track to increase our adjusted operating income margin above 31% by the end of 2028, reaffirming our commitment to solid profitable growth.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen reports Q3 adjusted EPS 57c, consensus 54c
- Qiagen announces FDA clearance for QIAstat-Dx Meningitis/Encephalitis Panel
- QGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Qiagen announces FDA clearance of QIAstat-Dx Respiratory Panel Mini test
- Qiagen downgraded to Hold from Buy at HSBC